These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8084487)

  • 1. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine.
    Rutter JJ; Gundlah C; Auerbach SB
    Neurosci Lett; 1994 Apr; 171(1-2):183-6. PubMed ID: 8084487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute uptake inhibition increases extracellular serotonin in the rat forebrain.
    Rutter JJ; Auerbach SB
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1319-24. PubMed ID: 7685386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex.
    Invernizzi R; Bramante M; Samanin R
    Pharmacol Biochem Behav; 1996 May; 54(1):143-7. PubMed ID: 8728551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of chronic fluoxetine treatment in the presence and absence of (+/-)pindolol: a microdialysis study.
    Dawson LA; Nguyen HQ; Smith DI; Schechter LE
    Br J Pharmacol; 2000 Jun; 130(4):797-804. PubMed ID: 10864885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist.
    Page ME; Cryan JF; Sullivan A; Dalvi A; Saucy B; Manning DR; Lucki I
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1220-7. PubMed ID: 12183683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation.
    Rutter JJ; Gundlah C; Auerbach SB
    Synapse; 1995 Jul; 20(3):225-33. PubMed ID: 7570354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic neurochemical and behavioral effects of fluoxetine and 5-HT1A receptor antagonists.
    Trillat AC; Malagié I; Mathe-Allainmat M; Anmella MC; Jacquot C; Langlois M; Gardier AM
    Eur J Pharmacol; 1998 Sep; 357(2-3):179-84. PubMed ID: 9797034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex.
    Dawson LA; Nguyen HQ; Smith DL; Schechter LE
    J Psychopharmacol; 2002 Jun; 16(2):145-52. PubMed ID: 12095073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.
    Gundlah C; Martin KF; Heal DJ; Auerbach SB
    J Pharmacol Exp Ther; 1997 Nov; 283(2):581-91. PubMed ID: 9353373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
    van Amsterdam C; Seyfried CA
    Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible in vivo 5-HT reuptake blocking properties of 8-OH-DPAT assessed by measuring hippocampal extracellular 5-HT using microdialysis in rats.
    Assié MB; Koek W
    Br J Pharmacol; 1996 Nov; 119(5):845-50. PubMed ID: 8922730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors.
    Tordera RM; Monge A; Del Río J; Lasheras B
    Eur J Pharmacol; 2002 May; 442(1-2):63-71. PubMed ID: 12020683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist apomorphine.
    Freo U; Merico A; Ermani M; Ori C
    Brain Res; 2010 Jun; 1335():24-34. PubMed ID: 20381465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
    Hughes ZA; Starr KR; Langmead CJ; Hill M; Bartoszyk GD; Hagan JJ; Middlemiss DN; Dawson LA
    Eur J Pharmacol; 2005 Mar; 510(1-2):49-57. PubMed ID: 15740724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.
    Felton TM; Kang TB; Hjorth S; Auerbach SB
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):297-305. PubMed ID: 12644903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine.
    Rasmussen K; Calligaro DO; Czachura JF; Dreshfield-Ahmad LJ; Evans DC; Hemrick-Luecke SK; Kallman MJ; Kendrick WT; Leander JD; Nelson DL; Overshiner CD; Wainscott DB; Wolff MC; Wong DT; Branchek TA; Zgombick JM; Xu YC
    J Pharmacol Exp Ther; 2000 Aug; 294(2):688-700. PubMed ID: 10900249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo.
    Sharp T; Umbers V; Gartside SE
    Br J Pharmacol; 1997 Jul; 121(5):941-6. PubMed ID: 9222551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of acoustic startle reactivity by cocaine administration during the postnatal period: comparison with a specific serotonin reuptake inhibitor.
    Dow-Edwards DL
    Neurotoxicol Teratol; 1996; 18(3):289-96. PubMed ID: 8725641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram.
    Arborelius L; Nomikos GG; Hertel P; Salmi P; Grillner P; Höök BB; Hacksell U; Svensson TH
    Naunyn Schmiedebergs Arch Pharmacol; 1996 May; 353(6):630-40. PubMed ID: 8738296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Destruction of serotonergic nerve terminals prevents fluoxetine-induced desensitization of hypothalamic 5-HT(1A) receptors.
    D'Souza DN; Zhang Y; Garcia F; Battaglia G; Van De Kar LD
    Psychopharmacology (Berl); 2002 Dec; 164(4):392-400. PubMed ID: 12457269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.